(Alliance News) - Scancell Holdings PLC on Monday said it has in-licensed SNAPvax technology from Vaccitech PLC to help develop its cancer treatments.
The agreement will allow the Nottingham-based cancer immunotherapies developer to formulate and manufacture Modi-2 with the aim of initiating a Phase 1 clinical study in cancer patients in 2024.
Modi-2 is the second product from Scancell's Moditope platform, which leverages the immune system to target a unique class of post-translational modifications upregulated by many cancers. Upregulation is the process by which a cell increases its response to a substance or signal from outside the cell to carry out a specific function.
Scancell expects that the combination of its Modi-2 with a "highly effective platform" for inducing T cells - Vaccitech's SNAPvax technology - will lead to a "potentially superior" therapeutic vaccine candidate.
Chief Executive Officer Lindy Durrant said: "We are pleased to partner with Vaccitech to take the second candidate from our Moditope platform through good manufacturing practice and subsequent clinical development. With its elegant and effective solution, the SNAPvax technology provides an excellent method for formulation of the Modi-2 vaccine. Combining this technology with our expertise will allow us to develop a rapid manufacturing process for Modi-2, with the hope that we can bring it into a Phase 1 clinical study during 2024."
Shares in Scancell Holdings were trading 4.4% higher at 19.98 pence each in London on Monday around midday.
By Chris Dorrell; chrisdorrell@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Scancell Holdings (SCLP)